Sedana Medical AB’s Year-end report 2023
Full year sales at upper end of financial guidance and an exciting year aheadFourth quarter 2023 · Net sales for the quarter totalled MSEK 44.5 (35.8), equivalent to an increase of 24% compared to the same quarter 2022. At constant exchange rates, sales increased by 18%. · Gross profit was MSEK 31.0 (25.7) equivalent to a margin of 70% (72%). · Earnings before interest, taxes, depreciation and amortisation (EBITDA) totalled MSEK -9.1 (-17.6), equivalent to an EBITDA margin of -20% (-49%). EBITDA ex-US for the quarter was MSEK -8.1 (-17.4) corresponding to a margin of -19% (-49%).